Vanda Pharmaceuticals
Washington, United States · Biopharma, Biotechnology, Health Care
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Key facts
- Headquarters
- Washington, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (VNDA)
- Website
- vandapharma.com
- Company page
Recent activity at Vanda Pharmaceuticals
- : GW Athletics partners with Vanda Pharmaceuticals for jersey patch collaboration.
- : Vanda Pharmaceuticals Inc. Announces Resignation of Senior Executive
- : SEC 8-K (5.02): On March 29, 2026, Timothy Williams notified Vanda Pharmaceuticals Inc. of his resignation as the Company’s Senior Vice President, General Counsel and Secretary. His resignation will be effective as of April 10, 2026, as he seeks to pursue other endeavors. This change in the executive team may have implications for the Company's legal and governance strategies moving forward, particularly given Williams' senior role. The Company will need to transition responsibilities and may identify a successor in the coming weeks.
- : SEC 8-K (5.02): On March 29, 2026, Timothy Williams resigned from his position as Senior Vice President, General Counsel, and Secretary of Vanda Pharmaceuticals Inc., with his resignation effective on April 10, 2026. His decision to leave the company is to pursue other endeavors. This leadership change may impact the company's governance, particularly in legal and compliance matters, following his departure.
- : SEC 8-K (7.01): On March 10, 2026, Mihael Polymeropoulos, M.D., President, CEO, and Chairman of Vanda Pharmaceuticals Inc., discussed the company's pricing and commercial strategy for NEREUS TM, a drug approved by the FDA for preventing motion-induced vomiting. He announced the upcoming development of NEREUSRX TM, which will provide direct-to-consumer access to NEREUS TM, set to launch in the next couple of months. This strategic move indicates Vanda's commitment to expanding its market reach and improving accessibility to its new product.
- : SEC 8-K (8.01): On February 20, 2026, Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Bysanti TM (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, as well as for the treatment of schizophrenia in adults. This approval represents a significant advancement in the treatment options for these mental health conditions, potentially leading to broader market access and enhanced revenue opportunities for Vanda. The press release detailing the approval is attached as Exhibit 99.1. The strategic implications of this approval could positively impact Vanda's positioning in the psychiatric pharmaceutical market.
- : SEC 8-K (8.01): On December 30, 2025, Vanda Pharmaceuticals Inc. announced through a press release that the U.S. Food and Drug Administration has approved NEREUS TM (tradipitant) for the prevention of vomiting induced by motion. This regulatory approval is significant as it positions Vanda to potentially capture a new market segment associated with motion sickness, improving its product offerings. The press release outlines the implications of this approval for future sales and marketing strategies, showcasing Vanda's commitment to advancing treatments for patients suffering from motion sickness.
Leadership
- Scott Howell, Chief People Officer ◆ 300+ Employees ◆ 4 Countries ◆ $250M in Revenue
- Timothy Williams, General Counsel
Verified email and direct lines for Vanda Pharmaceuticals’s decision-makers are on Fundz. See plans
Employee benefit plans
Vanda Pharmaceuticals files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Vanda Pharmaceuticals in the news
- Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results - prnewswire.com (May 06, 2026)
- Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - prnewswire.com (Feb 11, 2026)
- Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors - prnewswire.com (Apr 22, 2026)
- Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines - prnewswire.com (Apr 09, 2026)
- Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - prnewswire.com (Dec 30, 2025)
- Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation - prnewswire.com (Feb 20, 2026)
- Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting - prnewswire.com (Nov 17, 2025)
- Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results - prnewswire.com (Oct 29, 2025)
Companies similar to Vanda Pharmaceuticals
- Salarius Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Monopar Therapeutics · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Delta-Fly Pharma · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Aculys Pharma · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Bio-Convert ApS · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Vanda Pharmaceuticals: questions and answers
What does Vanda Pharmaceuticals do?
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Where is Vanda Pharmaceuticals headquartered?
Vanda Pharmaceuticals is headquartered in Washington, United States.
What is the latest news on Vanda Pharmaceuticals?
On Jun 26, 2026, GW Athletics partners with Vanda Pharmaceuticals for jersey patch collaboration.
Is Vanda Pharmaceuticals a public company?
Yes. Vanda Pharmaceuticals is publicly traded under the ticker VNDA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy